Share stock

Cryoport, Inc. Expected to Post Fiscal 2024 Earnings of $0.38 Per Share (NASDAQ:CYRX)

Cryoport, Inc. (NASDAQ:CYRX – Get Rating) – KeyCorp investment analysts lowered their fiscal 2024 earnings per share estimates for Cryoport shares in a research report released Thursday, May 5. KeyCorp analyst P. Knight now expects the consumer goods maker to post earnings per share of $0.38 for the year, down from its previous estimate of 0.49. $.

Several other research companies have also recently weighed in on CYRX. Needham & Company LLC reaffirmed a “buy” rating and set a price target of $45.00 on Cryoport shares in a Wednesday, April 13 report. Roth Capital lowered its price target on Cryoport shares from $90.00 to $67.00 in a Tuesday, May 3 report. TheStreet downgraded Cryoport’s shares from a “c-” rating to a “d+” rating in a Friday, January 28 research note. B. Riley reduced his target price on Cryoport shares from $94.00 to $70.00 in a Wednesday, March 2 research note. Finally, SVB Leerink raised its price target on Cryoport shares from $75.00 to $92.00 and gave the stock an “outperform” rating in a Friday, February 25 research note. One equity research analyst gave the stock a hold rating and six gave the stock a buy rating. According to data from MarketBeat, Cryoport currently has a consensus rating of “Buy” and an average price target of $61.14.

CYRX opened at $23.78 on Monday. The company has a current ratio of 16.26, a quick ratio of 15.88 and a debt ratio of 0.64. The company’s fifty-day moving average price is $30.29 and its two-hundred-day moving average price is $47.35. Cryoport has a 1-year low of $21.61 and a 1-year high of $86.30. The company has a market capitalization of $1.18 billion, a price-earnings ratio of -3.89 and a beta of 1.30. Cryoport (NASDAQ:CYRX – Get Rating) last released its quarterly earnings data on Thursday, May 5. The consumer goods maker reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.13). Cryoport had a negative return on equity of 13.57% and a negative net margin of 128.78%. The company posted revenue of $52.30 million for the quarter, versus analyst estimates of $52.86 million. In the same quarter of the previous year, the company posted EPS of ($0.13). The company’s quarterly revenue fell 1.9% year over year.

(A d)

Whether you’re looking to learn the basics of futures or you’re a seasoned veteran looking to hone your trading skills, our technical analysis guide has everything you need to succeed in today’s futures markets. today!

Separately, CEO Jerrell Shelton sold 3,298 shares in a trade dated Wednesday, March 9. The shares were sold at an average price of $31.05, for a total transaction of $102,402.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, accessible via this hyperlink. Additionally, CFO Robert Stefanovich sold 1,095 shares in a trade dated Wednesday, March 9. The shares were sold at an average price of $31.05, for a total transaction of $33,999.75. The disclosure of this sale can be found here. In the past 90 days, insiders have sold 5,803 shares of the company valued at $180,183. 9.70% of the shares are held by insiders of the company.

Hedge funds and other institutional investors have recently increased or reduced their stakes in the company. Captrust Financial Advisors increased its holdings in Cryoport by 35.4% during the third quarter. Captrust Financial Advisors now owns 624 shares of the consumer goods maker valued at $42,000 after buying an additional 163 shares in the last quarter. Pinebridge Investments LP acquired a new stake in Cryoport during the fourth quarter valued at approximately $77,000. Lindbrook Capital LLC purchased a new stake in Cryoport during the fourth quarter valued at approximately $87,000. FinTrust Capital Advisors LLC increased its holdings in Cryoport by 47.1% during the third quarter. FinTrust Capital Advisors LLC now owns 2,212 shares of the consumer goods maker valued at $147,000 after buying 708 additional shares in the last quarter. Finally, Parallel Advisors LLC acquired a new stake in Cryoport during the fourth quarter worth approximately $158,000.

About Cryoport (Get an assessment)

Cryoport, Inc, a life science services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa and Asia-Pacific. The Company offers Cryoportal, a cloud-based logistics management platform that supports shipment management, which includes order entry, document preparation, customs documentation, courier management, tracking and real-time shipment monitoring, problem resolution and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure the stability of shipped biologics is maintained throughout the shipping cycle.

Read more

Earnings History and Estimates for Cryoport (NASDAQ:CYRX)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Cryoport right now?

Before you consider Cryoport, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market goes big…and Cryoport wasn’t on the list.

Although Cryoport currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here